Author: Laia Romero

https://accure.health/accure-therapeutics-enrols-first-patient-in-phase-ii-clinical-trial-on-acute-optic-neuritis-with-lead-candidate-act-01/

https://www.asebio.com/actualidad/noticias/asebio-une-las-principales-gestoras-especializadas-de-capital-riesgo-para

https://mybinxhealth.com/news/binx-health-enters-into-distribution-agreement-for-national-launch-of-the-fda-cleared-binx-io/

https://accure.health/accure-therapeutics-publishes-pivotal-preclinical-efficacy-study-in-epilepsy/

https://www.sanifit.com/sanifit-granted-orphan-drug-designation-by-the-fda-for-snf472-for-the-treatment-of-peripheral-arterial-disease-in-patients-with-end-stage-kidney-disease/

https://accure.health/webinars-on-neuroprotection-for-brain-diseases-program/

https://www.plantadoce.com/empresa/alta-life-sciences-engorda-en-el-ano-del-covid-19-el-fondo-de-altamar-invierte-veinte-millones.html

https://accure.health/accure-therapeutics-appoints-dr-rossella-medori-as-chief-medical-officer/

• The financing round is led by Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC. Existing investors including Institut Català de Finances (ICF) have also participated in the financing. • Inbiomotion is in advanced stage of development of a single gene-based test for predicting response to bisphosphonates in breast cancer adjuvant setting and prevent metastasis. • The capital increase is intended to complete regulatory…

Five neurology experts join CNS specialist’s scientific advisory board to support clinical trial development of disease modifying drug candidates  Barcelona, Spain, January 11, 2021 – Accure Therapeutics, a private translational R&D engine at clinical stage in the Central Nervous System (CNS) field, today announces the appointment of five world-class neurology experts to its scientific advisory board. They will help boost innovation and advocate for Accure Therapeutics, as the company drives…